Loading clinical trials...
Loading clinical trials...
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Conditions
Interventions
Dabrafenib
Laboratory Biomarker Analysis
+3 more
Locations
2
United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
May 29, 2014
Primary Completion Date
March 31, 2019
Completion Date
October 26, 2022
Last Updated
October 16, 2024
NCT04879121
NCT04693377
NCT03907475
NCT06500455
NCT06311214
NCT05372640
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions